ALK-Positive Non-Small Cell Lung Cancer Overview
Learn About ALK-Positive Non-Small Cell Lung Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Cardiothoracic Surgeons Inc
Chadrick Denlinger is a Thoracic Surgeon in Indianapolis, Indiana. Dr. Denlinger and is rated as an Advanced provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Esophageal Perforation, Pleuropulmonary Blastoma, Endoscopy, and Gastrostomy. Dr. Denlinger is currently accepting new patients.
University Medical Diagnostic Associates Inc
Shadia Jalal is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Jalal and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma. Dr. Jalal is currently accepting new patients.
University Medical Diagnostic Associates Inc
Ahmad Al-Hader is an Intensive Care Medicine specialist and a Hematologist in Indianapolis, Indiana. Dr. Al-Hader has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Al-Hader is currently accepting new patients.
Summary: The goal of this clinical research study is to learn if the combination of brigatinib and either local consolidation therapy (such as radiotherapy or surgery) or chemotherapy (pemetrexed and carboplatin) can help to control the disease compared with brigatinib alone. The safety of these combinations will also be studied.
Summary: The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.